Public Health Agency of Canada
Symbol of the Government of Canada

Publicly Funded Immunization Programs in Canada - Routine Schedule for Infants and Children including special programs and catch-up programs (as of September, 2014)

Information on immunization programs was collected by the Canadian Nurses Coalition on Immunization (CNCI). PHAC and the CNCI have worked together since July 2004 to develop this tool containing the latest provincial/territorial program information.

Routine Schedule for Infants and Children
Province or Territory DTaP-IPV-Hib DTaP-IPV Tdap or Tdap-IPV HB MMR Var MMR-Var Men-C Men-C-A CYW-135 Pneu-
C-13
Inf HPV Rot
Legend:
DTaP:
Diphtheria, Tetanus, Acellular Pertussis
HB:
Hepatitis B
Hib:
Haemophilus Influenzae Type b
HPV:
Human Papillomavirus
Inf:
Influenza
IPV:
Inactivated Poliomyelitis
Men-C:
Meningococcal conjugate
MMR:
Measles, Mumps, Rubella
MMR-Var:
Measles, Mumps, Rubella, and Varicella
Pneu-C-13:
Pneumococcal conjugate 13 valent
Pneu-P-23:
Pneumococcal polysaccharide 23 valent
Rot:
Rotavirus
Tdap:
Tetanus, Diptheria, Acelluar Pertussis
Var:
Varicella
HR:
Children at high risk only (Definitions of High Risk for Publicly-funded Vaccines by Province/Territory)
Source: Canadian Nurses Coalition on Immunization, 2013
Recommended use:
  1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations (PDF Document - 712 Kb - 40 pages)
  2. The HPV vaccine is recommended for females (HPV2 or HPV4) and males (HPV4) between 9 and 26 years of age.
    Update On Human Papillomavirus (HPV) Vaccines
NACI recom-
mendation
2, 4, 6, 18 mths 4-6 yrs 14-16 yrs Infancy
(3 doses)
OR
Pre-teen/teen

(2-3 doses)
12 mths
AND
18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12-18 mths
AND
18 mths OR
4-6 yrs
OR
MMR-Var 2 doses
12 mths
AND
18 mths OR
4-6 yrs
Infancy (1-4 doses)Footnote 1 AND Pre-teen (1 dose)Footnote 1 Pre-teen (1 dose)Footnote 1 2, 4, 6, 12-15 mths 6-59 mths
(1-2 doses)
9-18 yrs
(3 doses at 0, 2, 6 mths)Footnote 2
2, 4, 6 mths
BC 2, 4, 6 (DTaP- HB-IPV-Hib),
18 mths
(DTaP-IPV-Hib)
4-6 yrs Tdap,
Gr. 9
2, 4, 6 mths (DTaP- HB-IPV-Hib) 12 mths
12 mths, 4-6 yrs beginning July 2014 2, (4 HR), 12 mths,
Gr. 6
  2, 4, (6 HR), 12 mths 6-59 mths Females,
Gr. 6  (2 doses 6 months apart),
Gr. 9 (3rd dose)
2, 4 mths
AB 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 9
Gr. 5     12 mths, 4-6 yrs 2, 4, 12 mths Grade 9
(1 dose)
2, 4, (6 HR), 12 mths ≥ 6 mths Gr. 5
Catch-up
Males
Gr. 9
 
SK 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 8
Gr. 6   Catch-up Gr. 6 until Aug 2015 12, 18 mths 12 mths Gr. 6 2, 4, (6 HR), 12 mths ≥ 6 mths Females
Gr. 6
2, 4 mths
MB 2, 4, 6, 18 mths   Tdap-IPV
4-6 years
Tdap, 14-16 yrs
Gr. 4     12 mths, 4-6 yrs (started 1 Apr 2014) 12 mths, Gr. 4 until 2017   2, 4, (6 HR), 12 mths ≥ 6 mths Females
Gr. 6;
2, 4 months (started 1 Apr 2014)
ON 2, 4, 6, 18 mths   Tdap-IPV 4-6 yrs, Tdap 14-16 yrs Gr. 7 12 mths 15 mths 4-6 yrs 12 mths  Gr. 7 2, 4, (6 HR), 12 mths ≥6 mths Females
Gr. 8
Catch-up until Gr. 12
2, 4 mths
QC 2, 4, 18 (DTaP- HB-IPV-Hib), 6 mths (DTaP-IPV-Hib)   Tdap-IPV 4-6 yrs,
Tdap 3rd year of high school
2, 4, 18 (DTaP- HB-IPV-Hib), Gr. 4 12 mths   18 mths 12 mths, 3rd year of high school; Catch-up < 18 yrs   2, 4, 12 mths 6-23 mths Females
Gr. 4; Catch-up Females < 18 yrs
2, 4 mths
NB 2, 4, 6, 18 mths 4 yrs (DTaP-IPV or Tdap-IPV) Tdap,
Gr. 7
0, 2, 6 mths   One dose children born between 2000 and 2008; Catch-up 2 doses children born in 2009 or later 12, 18 mths 12 mths Gr. 9 2, 4, 12 mths 6 mths – 18 yrs Females
Gr. 7
 
NS 2, 4, 6, 18 mths   Tdap-IPV 4-6 yrs, Tdap,
Gr. 7
Gr. 7     12 mths, 4-6 yrs 12 mths, Gr. 7   2, 4, 12 mths ≥ 6 mths Females
Gr. 7
 
PE 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 9
2, 4, 18 mths     12, 18 mths 12 mths Gr. 9 2, 4, (6 HR), 18 mths 6-59 mths Gr. 6 2, 4 mths
NL 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 9
Gr. 6     12, 18 mths 12 mths Gr. 4 2, 4, 12 mths ≥ 6 mths Females
Gr. 6
 
NT 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 9
0, 1, 6 mths; Catch-up Gr.9   Catch-up <5 yrs, Gr.9 (students who have received only 1 dose prior)) Catch-up
Pre-kindergarten, ≤ 12 yrs (school)
  2, 12 mths;
Catch-up <5 yrs, Gr. 9
Gr. 12 students who will be attending post secondary education outside NT 2, 4, 6, 18 mths ≥ 6 mths Females Gr.4;
Catch-up Gr.9-12
2009-14
2, 4 mths
YT 2, 4, 6 (DTaP- HB-IPV-Hib), 18  mths (DTaP-IPV-Hib) 4-6 yrs
(DTaP-IPV or Tdap-IPV)
Tdap,
Gr. 9
2, 4, 6 mths (DTaP- HB-IPV-Hib); Catch-up ≤19 yrs 12 mths, 4-6 yrs 12 mths,
4-6 yrs
  2, 12 mths; Gr. 6, post-secondary students not previously immunized   2, 4, (6 HR), 12 mths
(3 doses) (4 dose series for high risk)
1 dose for HIV+ ≥60 months of age not previously immunized)
> 6mths Females
Gr. 6
2, 4 mths
NU 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 9
(14-16 yrs)
0, 1, 9 mths 12, 18 mths; Catch-up
Gr. 12
15 mths   12 mths;
Catch-up Gr. 9 (14-16 yrs)
  2, 4, 6, 15 mths, plus Pneu-P-23 (1 dose) 2-3 yrs Universal ≥ 6 mths Females Gr. 6
(≥ 9 yrs)